ONCOFoCUS

환자가 열성 호중구 감소증의 위험이있는 경우 FN 앱을 평가한다.

ONCOFoCUS Febrile Neutropenia Risk Assessment. The application allows you to assess if a patient undergoing chemotherapy is at risk of febrile neutropenia. Through a series of standardised questions based on EORTC and NCCN guidelines, the tool asks you to consider the numerous factors that may contribute to an increased risk.

Benefits

· It allows you to reference the EORTC and NCCN estimated risk associated with Febrile Neutropenia across all of the major chemotherapy regimes.

·All of the content is accessible via your mobile device, this means you can access the content “on the go”, to allow for fast, efficient decision making.

- The results of your assessments can be shared with colleagues via PDF and saved within the history section of the application. This facilitates collaboration with your colleagues.

ONCOFoCUS This tool is offered to you as a part of Teva's OncoFocus initiative. OncoFocus (Zoom on people) is our commitment to support the patient and the Healthcare professional across the continuum of care throughout the patient journey.